News

A 2024 survey finds that most healthcare providers believe quality of life should be considered as much as symptom control when managing bipolar I disorder and schizophrenia.

Data from the phase 3 ATLAS trial supported Qfitlia's BLA, with the latest data presented at December’s ASH meeting.

Mantzoros explains factors contributing to the growing burden of MASLD and the need for collaboration between hepatology, primary care, and endocrinology.

Treprostinil (YUTREPIA) was previously granted tentative approval on August 16, 2024.

Study finds positive association between weight-adjusted waist index and risk of age-related macular degeneration in adults aged 40 or over.

In this video, the last in a 4-part series, panelists discuss how ongoing research and efforts could shape the future of ATTR-CM management.

In this video, part 3 of a 4-part series, panelists discuss the impact of recent approvals and pipeline developments on the outlook for ATTR-CM management.

In this video, part 2 of a 4-part series, panelists discuss on recent advancements in imaging and biomarker-based diagnostics for ATTR-CM

In this video, part 1 of a 4-part series, panelists discuss recent advancements in ATTR-CM management.

A study found omalizumab enables faster, safer desensitization in children with food allergies, improving oral immunotherapy outcomes and reducing reactions.

OAC-naive patients experienced a significantly smaller increase in stroke or systemic embolism with asundexian than apixaban.

A look at 7 phase 2 and phase 3 trials with significant implications from ACC 2025's late-breaking and featured clinical research sessions.

First Procedure Performed at AHN Wexford Hospital, Demonstrating Network’s Ongoing Commitment to Bringing Complex Cardiovascular Care into the Community

The AI-powered trial was officially initiated in January 2025.

These data point to the role of environmental factors in the development of atopic dermatitis and indicate targeted prevention strategies for those known to be impacted.

The new guideline provides healthcare providers, people living with ADPKD, and stakeholders with practical tools to improve diagnosis, care, and treatment.

Kwo explains why hepatitis A and B vaccination is important for people with liver disease and reviews different vaccine options.

Sidonio discussed how fitusiran may improve the treatment landscape and reduce treatment burden for people with hemophilia A or B with or without inhibitors.

Dara explains the importance of distinguishing DI-ALH from classic AIH, how their management differs, and where research in this field is heading.

Hong Kong schoolchildren exhibit increased rates of refractory and corneal astigmatism due to screen exposure during lockdown.

In this analysis, the investigators evaluated the temporal increase in hair shedding amounts following topical minoxidil utilization.

The FDA approval of diazoxide choline extended-release tablets (Vykat XR) was announced on March 26, 2025.

A meta-analysis of 27 trials found no increased risk of suicide or self-harm with GLP-1 RAs, supporting their safety for diabetes and obesity management.

Tabrizian discusses neoadjuvant immunotherapy for HCC, describing its success in the adjuvant setting but uncertainties about its use before transplant.

A phase 1 study found neffy nasal spray provides effective epinephrine absorption in children, supporting its role as a needle-free anaphylaxis treatment.

This quiz, the first in 4 part series, focuses on pivotal data from the INTEGUMENT trials in atopic dermatitis.

A Q2 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for dupilumab, pz-cel, ketamine, clesrovimab, and more!

Dara describes similarities between drug-induced autoimmune-like hepatitis and idiopathic autoimmune hepatitis, as well as how to differentiate them.